Lung cancer is the leading cause of cancer death worldwide, with an estimated 2.6 million new cases and 1.8 million deaths globally in 2024. A significant challenge is that two-thirds of patients are diagnosed at advanced stages, limiting therapeutic options and prognosis.
Targeted therapies have advanced in recent years, but require rapid and reliable knowledge of a tumor's genetic characteristics for personalized treatment and improved survival. As obtaining tumor samples can be difficult, liquid biopsy, which detects tumor DNA released into the blood, is emerging as a non-invasive alternative.
The team from the Liquid Biopsy Group at IDIPHISA and the Medical Oncology Service at Puerta de Hierro Majadahonda University Hospital has validated the next-generation sequencing (NGS) panel Illumina Solid Tumor Panel 80 (IST80 Plus). This tool precisely analyzes over 80 genes related to various cancers, including lung cancer, from a blood sample.
The study, published in The Journal of Liquid Biopsy and led by Dr. Pilar Mediavilla Medel and Dr. Atocha Romero, represents a significant step towards precision medicine.
Liquid biopsy allows for the detection of circulating tumor DNA (ctDNA) in the blood, providing information on mutations, tumor monitoring, and treatment response, without the need for invasive procedures like punctures or surgeries.
The new IST80 Plus tool analyzed 87 cancer-related genes. Out of 135 detectable alterations, it identified 129, achieving a sensitivity of 95.56% and a specificity close to 100% in mutation detection. The authors note that negative results should be interpreted with caution.
This advance in personalized oncology facilitates the analysis of tumor genetic alterations through a simple blood draw, avoiding invasive procedures and improving the acquisition of molecular information. While the results are promising, further research is needed to confirm its utility in a larger patient cohort.




